Stories
Slash Boxes
Comments

SoylentNews is people

posted by martyb on Friday October 14 2016, @04:44AM   Printer-friendly
from the fat-chance dept.

Current anti-obesity medications are only partly effective, due to substantial side effects, the temporary nature of the weight loss and the non-responsiveness of a considerable number of patients.

In a recently published series of studies led by TSRI Assistant Professor Anutosh Chakraborty of the Florida campus of The Scripps Research Institute (TSRI), scientists have identified a new therapeutic target -- a key protein that promotes fat accumulation in animal models by slowing the breakdown and expenditure of fat and encouraging weight gain.

[...] The expenditure of fat energy is preceded by a process called lipolysis that breaks down stored fat or triglycerides (specifically into free fatty acids and glycerol) to be used as energy in cells. The team discovered that deletion of IP6K1 affects interaction with another regulating protein and enhances the breakdown of fats.

To determine the therapeutic possibilities of the IP6K1 pathway, the team looked at the impact of an IP6K inhibitor known as TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl) purine] on diet-induced obesity in animal models. As it turns out, TNP significantly slows the initiation of diet-induced obesity and insulin resistance.

Journal References:

  1. Qingzhang Zhu, Sarbani Ghoshal, Ana Rodrigues, Su Gao, Alice Asterian, Theodore M. Kamenecka, James C. Barrow, Anutosh Chakraborty. Adipocyte-specific deletion of Ip6k1 reduces diet-induced obesity by enhancing AMPK-mediated thermogenesis. Journal of Clinical Investigation, 2016; DOI: 10.1172/JCI85510
  2. Sarbani Ghoshal, Richa Tyagi, Qingzhang Zhu, Anutosh Chakraborty. Inositol hexakisphosphate kinase-1 interacts with perilipin1 to modulate lipolysis. The International Journal of Biochemistry & Cell Biology, 2016; 78: 149 DOI: 10.1016/j.biocel.2016.06.018
  3. Sarbani Ghoshal, Qingzhang Zhu, Alice Asteian, Hua Lin, Haifei Xu, Glen Ernst, James C. Barrow, Baoji Xu, Michael D. Cameron, Theodore M. Kamenecka, Anutosh Chakraborty. TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway. Molecular Metabolism, 2016; 5 (10): 903 DOI: 10.1016/j.molmet.2016.08.008

Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 2) by HiThere on Friday October 14 2016, @07:36PM

    by HiThere (866) Subscriber Badge on Friday October 14 2016, @07:36PM (#414418) Journal

    I tried that and my triglycerides went through the roof. I got off it and they *slowly* headed back down.

    What seems to work for me is avoiding *almost* all refined carbohydrates and sugars, combined with reasonable quantities of fiber. So, e.g., instead of flour I now use a mix of wheat bran and wheat germ. But I also don't totally avoid refined carbohydrates, as that's supposed to interfere with proper operation of the liver. I'm still working on recipes that will be satisfying, low in calories, low in starches, VERY low in sugars, and high in fiber. (This doesn't seem like the right place to post them.)

    --
    Javascript is what you use to allow unknown third parties to run software you have no idea about on your computer.
    Starting Score:    1  point
    Karma-Bonus Modifier   +1  

    Total Score:   2